Windlas Biotech Q2 Results and Board Leadership Restructuring
Windlas Biotech Ltd · Change in Management · 05 Nov 2026, 10:48 pm
Windlas Biotech Q2 Results and Board Leadership Restructuring Windlas Biotech reported Q2'27 revenue from operations of ₹2,639.08m, up 18.7% YoY and 6.4% QoQ, while net profit stood at ₹180.52m compared to ₹178.00m in Q2'26. For H1'27, revenue reached ₹5,120.07m with net profit at ₹357.05m. The Board approved the succession plan wherein Mr. Ashok Kumar Windlass resigned as Whole-time Director effective 5th Nov'26, transitioning to Founder President (SMP) from 6th Nov'26. Additionally, MD Mr. Hitesh Windlass was appointed as Chairman of the Board effective 5th Nov'26.
Original exchange filing (PDF)
More announcements from Windlas Biotech Ltd
- Q2 & H1 FY27 Earnings Conference Call Transcript · 13 Nov 2026
- Recording of Conference Call · 07 Nov 2026
- press release titled 'Windlas Biotech Limited Reports its H1 & Q2 FY27 Financial Results" · 05 Nov 2026
- Mr. Ashok Kumar Windlass, has been appointed, as Founder President (Senior Management Personnel) of the Company, effective from November 6, 2026. · 05 Nov 2026
- Investor Presentation - Q2 & H1FY27, · 05 Nov 2026
- Windlas Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 05 Nov 2026
- Approval inter alia unaudited financial results for the quarter and half year ended September 30, 2026 · 05 Nov 2026
- The Board approved inter alia financial results for the quarter and half year ended September 30 2026. · 05 Nov 2026
